Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy

Journal of Immunology

Volumn 169, Issue 9, 2002, Pages 4811-4821

  Peng, Liaomin ^a   Kjaergäard, Jørgen ^a   Plautz, Gregory E ^a   Awad, Mohamed ^a   Drazba, Judith A ^a   Shu, Suyu ^a   Cohen, Peter A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

L SELECTIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; EFFECTOR CELL; FEMALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REJECTION;

EID: 0036839149     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.9.4811     Document Type: Article

References (39)

1. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708.
2. Sallusto, F., E. Kremmer, B. Palermo, A. Hoy, P. Ponath, S. Qin, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur. J. Immunol. 29:2037.
3. Mackay. C. R., and U. H. von Andrian. 2001. Immunology: Memory T cells: Local heroes in the struggle for immunity. Science 291:2323.
4. Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291:2413.
5. Reinhardt, R. L., A. Khoruts. R. Merica, T. Zell, and M. K. Jenkins. 2001. Visualizing the generation of memory CD4 T cells in the whole body. Nature 410:101.
6. + memory T cell subsets in persistent EBV infection are differentiated by migratory receptor expression. Eur. J. Immunol. 30:1823.
7. Dunbar. P. R., C. L. Smith, D. Chao. M. Salio, D. Shepherd, F. Mirza, M. Lipp, A. Lanzavecchia, F. Sallusto. A. Evans, et al. 2000. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol. 165:6644.
8. Kagamu, H., J. E. Touhalisky, G. E. Plautz, J. C. Krauss, and S. Shu. 1996. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 56:4338.
9. Cohen, P. A., L. Peng, J. Kjaergäard. G. E. Plautz, J. H. Finke, G. K. Koski, B. J. Czerniecki, and S. Shu. 2001. T-cell adoptive therapy of tumors: Mechanisms of improved therapeutic performance. Crit. Rev. Immunol. 21:215.
10. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J. Immunol. 160:3444.
11. low T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression. J. Immunol. 165:5738.
12. Kjaergäard, J., and S. Shu. 1999. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J. Immunol. 163:751.
13. Mukai, S., J. Kjaergäard, S. Shu, and G. E. Plautz. 1999. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res. 59:5245.
14. Peng, L., S. Shu, and J. C. Krauss. 1997. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell. Immunol. 178:24.
15. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit. Rev. Immunol. 20:17.
16. Shevach, E. M., R. S. McHugh, A. M. Thornton, C. Piccirillo, K. Natarajan, and D. H. Margulies. 2001. Control of autoimmunity by regulatory T cells. Adv. Exp. Med., Biol. 490:21.
17. + immunoregulatory cells. J. Immunol. 167:1137
18. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25:207.
19. + T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103:449.
20. Cohen, P. A., D. J. Fowler, H. Kim, R. L. White, B. J. Czerniecki, C. Carter, R. E. Gress, and S. A. Rosenberg. 1994. Propagation of murine and human T cells with defined antigen specificity and function. In Ciba Foundation Symposium No. 187: Vaccines Against Virally Induced Cancers. I. Frazer, D. Chadwick, and J. Marsh, eds. Wiley, Chichester, U.K., p. 179.
21. Kjaergäard, J., L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu. 2001. Augmentation vs. inhibition: Effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J. Immunol. 167:6669.
22. North, R. J. 1985. Down-regulation of the antitumor immune response. Adv. Cancer Res. 45:1.
23. + T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells. Int. J. Cancer 55:338.
24. Dunn, P. L., and R. J. North. 1991. Selective radiation resistance of immunologically induced T cells as the basis for irradiation-induced T-cell-mediated regression of immunogenic tumor. J. Leukocyte Biol. 49:388.
25. Awad, M., and R. J. North. 1990. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. Cancer Res. 50:2228.
26. Broder, S., and T. A. Waldmann. 1978. The suppressor-cell network in cancer (first of two parts), N. Engl. J. Med. 299:1281.
27. Perry, L. L., B. Benacerraf, R. T. McCluskey, and M. I. Greene. 1978. Enhanced syngeneic tumor destruction by in vivo inhibition of suppressor T cells using anti-I-J alloantiserum. Am. J. Pathol. 92:491.
28. Vukmanovic-Stejic, M., M. J. Thomas, A. Noble, and D. M. Kemeny. 2001. Specificity, restriction and effector mechanisms of immunoregulatory CD8 T cells. Immunology. 102:115.
29. + regulatory T cells is mediated by cell surfacebound transforming growth factor β. J. Exp. Med. 194:629.
30. Gilliet, M., and Y. J. Liu. 2002. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 195:695.
31. Ganss, R., E. Ryschich, E. Klar, B. Arnold, and G. J. Hammerling. 2002, Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62:1462.
32. + T cells is induced by IL-2 receptor γ chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis. Int. Immunol. 12:1005.
33. Peng, L., J. C. Krauss, G. E. Plautz, S. Mukai, S. Shu, and P. A. Cohen. 2000. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-γ mechanisms that cannot be predicted from in vitro T cell characteristics. J. Immunol. 165:7116.
34. Shu, S. Y., T. Chou, and S. A. Rosenberg. 1987. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J. Immunol. 139:295.
35. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber. D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159.
36. Schwartzentruber, D. J., S. S. Horn, R. Dadmarz, D. E. White, J. R. Yannelli, S. M. Steinberg, S. A. Rosenberg, and S. L. Topalian. 1994. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 12:1475.
37. Pockaj, B. A., R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang. 1994. Localization of indium-III-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: Augmentation with cyclophosphamide and correlation with response. Cancer 73:1731.
38. Rosenberg, S. A., P. Aebersold, K. Cornetta, A. Kasid, R. A. Morgan, R. Moen, E. M. Karson. M. T. Lotze, J. C. Yang, and S. L. Topalian. 1990. Gene transfer into humans: Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323:570.
39. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.